MX2020013694A - Compuestos heterocíclicos como inhibidores de trk. - Google Patents
Compuestos heterocíclicos como inhibidores de trk.Info
- Publication number
- MX2020013694A MX2020013694A MX2020013694A MX2020013694A MX2020013694A MX 2020013694 A MX2020013694 A MX 2020013694A MX 2020013694 A MX2020013694 A MX 2020013694A MX 2020013694 A MX2020013694 A MX 2020013694A MX 2020013694 A MX2020013694 A MX 2020013694A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- trk inhibitor
- heterocyclic compound
- trk
- treating
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000155 isotopic effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a un compuesto, una composición farmacéutica que comprende el compuesto, el método para la preparación del mismo, y el uso del mismo como inhibidor de TRK; el compuesto es un compuesto mostrado en la fórmula I siguiente, e isómeros, profármacos, solvatos, derivados isotópicos estables o sales farmacéuticamente aceptables de los mismos; la presente invención también se refiere al uso del compuesto en el tratamiento o prevención de enfermedades mediadas por TRK, tales como cánceres, y métodos para el tratamiento de tales enfermedades usando los compuestos de la presente invención. (ver fórmula I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810660162.6A CN110627812B (zh) | 2018-06-25 | 2018-06-25 | 作为trk抑制剂的杂环化合物 |
| PCT/CN2019/092653 WO2020001415A1 (zh) | 2018-06-25 | 2019-06-25 | 作为trk抑制剂的杂环化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013694A true MX2020013694A (es) | 2021-05-27 |
Family
ID=68966871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013694A MX2020013694A (es) | 2018-06-25 | 2019-06-25 | Compuestos heterocíclicos como inhibidores de trk. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11878987B2 (es) |
| EP (1) | EP3822276A4 (es) |
| JP (1) | JP7372686B2 (es) |
| KR (1) | KR20210024043A (es) |
| CN (1) | CN110627812B (es) |
| AU (1) | AU2019296085B2 (es) |
| BR (1) | BR112020026653A2 (es) |
| CA (1) | CA3104377C (es) |
| MX (1) | MX2020013694A (es) |
| PH (1) | PH12020552244A1 (es) |
| SG (1) | SG11202013016YA (es) |
| TW (1) | TWI828712B (es) |
| WO (1) | WO2020001415A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11358973B2 (en) | 2018-04-16 | 2022-06-14 | Shenzhen Targetrx, Inc. | Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity |
| CN110627812B (zh) | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| WO2021042890A1 (zh) * | 2019-09-04 | 2021-03-11 | 罗欣药业(上海)有限公司 | 杂环化合物及其作为Trk激酶抑制剂的应用 |
| CN115884776A (zh) * | 2021-06-15 | 2023-03-31 | 中国医药研究开发中心有限公司 | 杂环大环化合物及其医药用途 |
| CN113444070A (zh) * | 2021-07-28 | 2021-09-28 | 深圳市真味生物科技有限公司 | 一种由手性叔丁基亚磺酰胺合成手性尼古丁的制备方法 |
| CN116554203A (zh) * | 2022-01-29 | 2023-08-08 | 南京天印健华医药科技有限公司 | 化合物的晶型及其制备方法 |
| CN117586277A (zh) * | 2022-08-09 | 2024-02-23 | 苏州朗睿生物医药有限公司 | 一种大环三氮唑衍生物及其制备方法和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57221B2 (sr) | 2008-10-22 | 2020-08-31 | Array Biopharma Inc | Jedinjenja supstituisanog pirazolo[1,5-]pirimidina kao inhibitori trk kinaze |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| RU2735545C2 (ru) * | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| ES2583477T3 (es) | 2011-09-30 | 2016-09-21 | Ipsen Pharma S.A.S. | Inhibidores macrocíclicos de cinasa de LRRK2 |
| SG10202000191YA (en) | 2014-01-24 | 2020-03-30 | Turning Point Therapeutics Inc | Diaryl macrocycles as modulators of protein kinases |
| RU2744852C2 (ru) | 2015-10-26 | 2021-03-16 | Локсо Онколоджи, Инк. | Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы |
| AU2018364938B2 (en) | 2017-11-10 | 2021-11-11 | Angex Pharmaceutical, Inc. | Macrocyclic compounds as TRK kinase inhibitors and uses thereof |
| WO2019149131A1 (zh) | 2018-01-30 | 2019-08-08 | 上海吉倍生物技术有限公司 | 具有大环分子结构的化合物及其用途 |
| CN110156813B (zh) | 2018-02-13 | 2023-07-25 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| US11358973B2 (en) | 2018-04-16 | 2022-06-14 | Shenzhen Targetrx, Inc. | Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity |
| CN110627812B (zh) | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
-
2018
- 2018-06-25 CN CN201810660162.6A patent/CN110627812B/zh active Active
-
2019
- 2019-06-25 US US17/255,797 patent/US11878987B2/en active Active
- 2019-06-25 EP EP19825716.4A patent/EP3822276A4/en active Pending
- 2019-06-25 JP JP2020572445A patent/JP7372686B2/ja active Active
- 2019-06-25 TW TW108122091A patent/TWI828712B/zh active
- 2019-06-25 CA CA3104377A patent/CA3104377C/en active Active
- 2019-06-25 BR BR112020026653-1A patent/BR112020026653A2/pt unknown
- 2019-06-25 SG SG11202013016YA patent/SG11202013016YA/en unknown
- 2019-06-25 AU AU2019296085A patent/AU2019296085B2/en active Active
- 2019-06-25 KR KR1020217001867A patent/KR20210024043A/ko active Search and Examination
- 2019-06-25 WO PCT/CN2019/092653 patent/WO2020001415A1/zh unknown
- 2019-06-25 MX MX2020013694A patent/MX2020013694A/es unknown
-
2020
- 2020-12-22 PH PH12020552244A patent/PH12020552244A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020026653A2 (pt) | 2021-03-23 |
| US20210147445A1 (en) | 2021-05-20 |
| EP3822276A1 (en) | 2021-05-19 |
| AU2019296085A1 (en) | 2021-01-28 |
| CA3104377C (en) | 2024-01-23 |
| AU2019296085B2 (en) | 2024-02-15 |
| JP2021529182A (ja) | 2021-10-28 |
| JP7372686B2 (ja) | 2023-11-01 |
| TWI828712B (zh) | 2024-01-11 |
| WO2020001415A1 (zh) | 2020-01-02 |
| EP3822276A4 (en) | 2022-04-06 |
| PH12020552244A1 (en) | 2021-06-28 |
| US11878987B2 (en) | 2024-01-23 |
| KR20210024043A (ko) | 2021-03-04 |
| SG11202013016YA (en) | 2021-02-25 |
| CA3104377A1 (en) | 2020-01-02 |
| TW202019939A (zh) | 2020-06-01 |
| CN110627812B (zh) | 2022-10-11 |
| CN110627812A (zh) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
| PH12019500036A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| MX2022006475A (es) | Compuestos triciclicos sustituidos. | |
| CR20210287A (es) | Inhibidores de cinasa 7 dependiente de ciclina (cdk7) | |
| TR201802944T4 (tr) | İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
| PH12020552017A1 (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| MX2019006843A (es) | Inhibidor de cdk4/6. | |
| MX2016008665A (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| PH12021550958A1 (en) | Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor | |
| WO2021012049A8 (en) | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors | |
| SA520411787B1 (ar) | مشتقات بنزيميدازول واستخداماتها | |
| MX2019010096A (es) | Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa. | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
| ZA202206481B (en) | Amide derivative and preparation method therefore and use thereof in medicine | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| BR112022001922A2 (pt) | Compostos de heteroarila de anel fundido como inibidores de ripk1 | |
| MX2020008498A (es) | Derivados de sobetirome. | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| MX2022003617A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer. |